Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
02 2021
Historique:
received: 28 02 2020
accepted: 21 09 2020
pubmed: 3 10 2020
medline: 8 9 2021
entrez: 2 10 2020
Statut: ppublish

Résumé

Tuberculosis is associated with a risk of immune reconstitution inflammatory syndrome (IRIS) after ART initiation. Data from all patients with newly diagnosed tuberculosis disease and uncontrolled HIV infection from 1997 to 2017 in a French center were retrospectively collected. We evaluated the incidence of tuberculosis-IRIS in patients initiating ART with or without integrase inhibitors (INSTI) RESULTS: Fifty-five patients were included: 21 receiving an INSTI regimen and 34 a non-INSTI regimen. Except with regard to ART regimen, the two groups were comparable (median CD4 of 85/mm

Sections du résumé

BACKGROUND
Tuberculosis is associated with a risk of immune reconstitution inflammatory syndrome (IRIS) after ART initiation.
METHODS
Data from all patients with newly diagnosed tuberculosis disease and uncontrolled HIV infection from 1997 to 2017 in a French center were retrospectively collected. We evaluated the incidence of tuberculosis-IRIS in patients initiating ART with or without integrase inhibitors (INSTI) RESULTS: Fifty-five patients were included: 21 receiving an INSTI regimen and 34 a non-INSTI regimen. Except with regard to ART regimen, the two groups were comparable (median CD4 of 85/mm

Identifiants

pubmed: 33007401
pii: S0399-077X(20)30703-4
doi: 10.1016/j.medmal.2020.09.005
pii:
doi:

Substances chimiques

Integrase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-93

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

A Gaillet (A)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France. Electronic address: gaillet.antoine75@gmail.com.

R Calin (R)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

P Flandre (P)

Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

R Tubiana (R)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

M-A Valantin (MA)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

E Caumes (E)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

C Katlama (C)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

V Pourcher (V)

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Inserm UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Université, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH